Pieris Pharmaceuticals, Inc. financial data

Symbol
PIRS on Nasdaq
Industry
Pharmaceutical Preparations
Location
225 Franklin Street, 26 Th Floor, Boston, MA
State of incorporation
Nevada
Fiscal year end
December 31
Former names
Marika Inc. (to 12/18/2014)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 190 % -22.1%
Debt-to-equity 137 % -22.5%
Return On Assets -62.4 % -110%
Operating Margin -124 % -10.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.32M shares -98.7%
Common Stock, Shares, Outstanding 1.32M shares -98.7%
Entity Public Float 11.2M USD -90.2%
Common Stock, Value, Issued 1K USD -99%
Weighted Average Number of Shares Outstanding, Basic 1.3M shares +18.6%
Weighted Average Number of Shares Outstanding, Diluted 1.3M shares +18.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 20.9M USD -37.1%
Research and Development Expense 16M USD -70.7%
General and Administrative Expense 16.7M USD +7.1%
Operating Income (Loss) -25.8M USD +30.6%
Net Income (Loss) Attributable to Parent -23.8M USD +11.9%
Earnings Per Share, Basic 3.54 USD/shares -176%
Earnings Per Share, Diluted -2.76 USD/shares -176%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.7M USD -56.1%
Cash, Cash Equivalents, and Short-term Investments 19.7M USD -64.1%
Accounts Receivable, after Allowance for Credit Loss, Current 1.49M USD +56%
Assets, Current 38.7M USD -47.3%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 25.1M USD -71.4%
Accounts Payable, Current 969K USD -87.3%
Employee-related Liabilities, Current 3.11M USD +46.3%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 6.35M USD -81.5%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD
Liabilities 11.9M USD -82.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -436K USD -218%
Retained Earnings (Accumulated Deficit) -323M USD -7.95%
Stockholders' Equity Attributable to Parent 18.7M USD -53.8%
Liabilities and Equity 25.1M USD -71.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7M USD +36.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 9M USD -24.4%
Common Stock, Shares Authorized 3.75M shares -98.8%
Common Stock, Shares, Issued 1.32M shares -98.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.69M USD +52.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 54.3M USD -54.4%
Deferred Tax Assets, Valuation Allowance 72.5M USD +19.7%
Deferred Tax Assets, Gross 72.5M USD +13.6%
Operating Lease, Liability 12.3M USD +0.62%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -24.1M USD +13.3%
Lessee, Operating Lease, Liability, to be Paid 18.4M USD -3.37%
Property, Plant and Equipment, Gross 26.7M USD +3.93%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.09M USD +7.91%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.09M USD +7.91%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.14M USD -10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.09M USD +7.91%
Deferred Tax Assets, Operating Loss Carryforwards 67.5M USD +23.1%
Preferred Stock, Shares Issued 15.6K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.09M USD +7.91%
Operating Lease, Payments 1.2M USD -45.5%
Additional Paid in Capital 343M USD +0.71%
Preferred Stock, Shares Outstanding 15.6K shares 0%
Depreciation, Depletion and Amortization 605K USD -28.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%